Department of Ophthalmology (O.O.U.), Ankara University School of Medicine, Ankara, Turkey; Department of Ophthalmology (T.C.-B.), Unye State Hospital, Ordu, Turkey; Department of Ophthalmology (L.Y.), University of Tennessee Health Science Center, Memphis, TN;Sidney Kimmel Medical College at Thomas Jefferson University (B.W.), Philadelphia, PA; and Department of Ophthalmology (P.A.A.), University of Tennessee Health Science Center, Memphis, TN.
Eye Contact Lens. 2023 Dec 1;49(12):542-568. doi: 10.1097/ICL.0000000000001026. Epub 2023 Sep 20.
Although the ultimate goal of dry eye disease (DED) management is to restore the ocular surface and tear film homeostasis and address any accompanying symptoms, addressing this is not an easy task. Despite the wide range of current treatment modalities targeting multiple aspects of DED, the available DED management literature is quite heterogeneous, rendering evaluation or comparison of treatment outcomes hard or almost impossible. There is still a shortage of well-designed, large-scale, nonsponsored, randomized, controlled trials (RCTs) evaluating long-term safety and efficacy of many targeted therapies individually or used in combination, in the treatment of identified subgroups of patients with DED. This review focuses on the treatment modalities in DED management and aims to reveal the current evidence available as deduced from the outcomes of RCTs.
尽管干眼症 (DED) 管理的最终目标是恢复眼表面和泪膜的稳态并解决任何伴随的症状，但这并非易事。尽管目前有针对 DED 多个方面的多种治疗方法，但现有的 DED 管理文献差异很大，使得治疗结果的评估或比较变得困难甚至几乎不可能。在治疗确定的 DED 患者亚组时，仍缺乏针对许多靶向治疗的单独或联合使用的设计良好、大规模、非赞助、随机、对照试验 (RCT)，以评估其长期安全性和有效性。本综述重点介绍 DED 管理中的治疗方法，并旨在根据 RCT 的结果揭示当前可获得的证据。
